Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398454 | 0.91 | S1PR1 (0.50) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398651 | 0.86 | S1PR1 (0.46) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL13361428 | 0.86 | S1PR1 (0.44) | S1PR1CYP2C9S1PR3RXFP1POLB | |
| SCHEMBL402115 | 0.84 | S1PR1 (0.51) | S1PR1S1PR3RXFP1POLB | |
| SCHEMBL1398648 | 0.84 | S1PR1 (0.46) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398559 | 0.82 | S1PR1 (0.48) | S1PR1S1PR3RXFP1POLB | |
| SCHEMBL3310448 | 0.80 | S1PR1 (0.48) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398520 | 0.79 | S1PR1 (0.76) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL3311215 | 0.78 | S1PR1 (0.60) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398479 | 0.77 | S1PR1 (0.61) | S1PR1CYP2C9S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2009-03-19 | — | — | US | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | S1PR1 502/4885CYP2C9 3613/4885S1PR3 364/4885 |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885CYP2C9 3130/4885S1PR3 2/4885 |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | S1PR1 502/4885CYP2C9 3613/4885S1PR3 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.